Covagen AG

Crafting next-generation therapies through innovative protein and antibody fusion for enhanced treatment of inflammatory diseases and cancer.

General Information
Company Name
Covagen AG
Founded Year
2007
Location (Offices)
+1
Founders / Decision Makers
Number of Employees
2
Industries
Biopharma, Biotechnology, Health and Wellness
Funding Stage
Series B
Social Media

Covagen AG - Company Profile

Covagen AG is a biopharmaceutical company with a specialized focus on crafting next-generation therapies through innovative protein and antibody fusion for enhanced treatment of inflammatory diseases and cancer. The company's unique approach involves creating bispecific FynomAbs by merging its human Fynomer binding proteins with antibodies, resulting in therapeutics with distinctive action mechanisms and improved effectiveness.

The capability to attach Fynomers to multiple sites on an antibody allows Covagen to develop FynomAbs with customized structures for optimal efficacy. Founded in 2007 as a spin-off from ETH Zurich (Swiss Federal Institute of Technology), Covagen has garnered substantial support from prominent investors such as Novartis Venture Fund, Edmond de Rothschild Investment Partners, Gimv, Seroba Kernel Life Sciences, Ventech, Ascent Biomedical Venture Management, MP Healthcare Venture Management, and Baxter Ventures.

Their main objective is to explore novel biological pathways for each product candidate, with a particular focus on their leading FynomAb, COVA322, which is being developed specifically for treating inflammatory conditions like rheumatoid arthritis and psoriatic arthritis. In October 2012, Covagen established a strategic research partnership and licensing agreement with Mitsubishi Tanabe / TRL to develop bispecific FynomAbs against targets chosen by Mitsubishi Tanabe / TRL.

The last investment in Covagen AG was a Fr.58.90M Series B investment on 09 December 2013, with participation from Novartis Venture Fund, Ventech Capital, GIMV, Ascent Biomedical Ventures, Baxter Ventures, MP Healthcare Venture Management, Seroba Life Sciences, Andera Partners, Edmond de Rothschild Private Equity.

Taxonomy: drug development, therapeutics, FynomAbs, protein fusion, antibody fusion, inflammatory diseases, cancer treatment, biological pathways, research partnership, spin-off company, investors, ETH Zurich, Novel modes of action, Strategic collaboration

Funding Rounds & Investors of Covagen AG (4)

View All
Funding Stage Amount No. Investors Investors Date
Series B Fr.58.90M 9 Edmond de Rothschild Private Equity 09 Dec 2013
Series A $6.30M 1 29 Nov 2010
Series A $34.20M - 01 Dec 2009
Seed Round Unknown - 05 Oct 2009

Latest News of Covagen AG

View All

No recent news or press coverage available for Covagen AG.

Similar Companies to Covagen AG

View All
(株)陽進堂 - Similar company to Covagen AG
(株)陽進堂 Pioneering the future of pharmaceuticals through innovative biopharmaceutical ventures and global biosimilar development.
Pharmacopeia - Similar company to Covagen AG
Pharmacopeia Innovating to meet critical health challenges with advanced therapeutic discoveries and developments.
Servatus Ltd - Similar company to Covagen AG
Servatus Ltd Developing novel microbiome-based treatments for autoimmune diseases, including rheumatoid arthritis, IBD and psoriasis.
Encysive Pharmaceuticals - Similar company to Covagen AG
Encysive Pharmaceuticals Leading the fight against vascular and inflammatory diseases with groundbreaking synthetic and small molecule compounds.